Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for regression of coronary atherosclerosis
2022-003381-21Phase 2Active
- Sponsor
- Psyon Therapeutics
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of psilocybin and midazolam in coronary arteriosclerosis and atherosclerosis (2 arms), sponsored by Psyon Therapeutics. Primary endpoint: Change in atherosclerotic plaque volume at 12 months. Started May 2023; status: active.
02
Drugs
psilocybinmidazolam
03
Conditions
coronary arteriosclerosisatherosclerosis
Beyond the preview
Go deeper on 2022-003381-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003381-21.